| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b5b9d38d7facab00f3bcd1e3b2bc8f2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55511 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H5-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H5-04 |
| filingDate |
2012-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b80932f6242c76f55b216809a649b79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1abe11c024052799467171efb808e473
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_193040e5e50d3927d49bdd51a73b83ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c03d732529e3ee1dbc872163d94ac560
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c282f22e39138258c71cd8e580c3d4c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_925d8acf4546a58da0c4581fd315ea2e |
| publicationDate |
2013-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013178613-A1 |
| titleOfInvention |
Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes |
| abstract |
The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9512158-B2 |
| priorityDate |
2006-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |